Compare General Dynamics Corporation (GD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Neurocrine Biosciences Inc — how do they compare? General Dynamics Corporation trades at $331.32 (market cap $88.37B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: General Dynamics Corporation is far larger — about 6.1× Neurocrine Biosciences Inc's market cap, and General Dynamics Corporation pays a 1.95% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GD | NBIX | |
|---|---|---|
Market Cap | $88.37B | $14.60B |
Volume | 1,251,409 | 1,075,694 |
Sector | Industrials | Health |
52-Week High | $395.97 | $185.50 |
52-Week Low | $312.53 | $123.10 |
Typical Hold Time | 85 Days | 23 Days |
Enterprise Value | $93.52B | $14.61B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, down 0.43% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, while technical indicators show oversold conditions with RSI at 11.03.
GD offers solid value with reasonable valuation multiples and strong defense contract visibility, though near-term technical weakness and dependence on government spending create volatility. The stock's 27% upside to consensus target and consistent dividend payments provide attractive total return potential for long-term investors.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
